1

Increasing Biotech Involvement in Global Health Innovation

Oxford Conference on Innovation and Technology Transfer for Global Health

September 11, 2007

James A. Geraghty

Genzyme Corporation

2

Objectives of today’s talk

Provide rationale/mandate for involvement

Outline possible approaches and contributions

Summarize one company’s involvement

Catalyze discussion and new initiatives

3

The Case for Corporate Involvement

To maintain policy support – regulatory, pricing, IP … To maintain long-term public trust and goodwill To attract and retain highly motivated employees To develop relationships in emerging markets To develop new capabilities through partnerships

Many agree – why isn’t more done?

Not charity- a strategic responsibility

4

(Perceived) Barriers to Involvement

“We’re not experts in these diseases”

“We can’t afford the expenses”

“It’s not in our shareholders’ interest”

“We’ll only spark more criticism”

5

Twin Pillars of Partnership

Access CriteriaIndustry Needs

Guiding Principles:

• Maximize access: developing countries

• Minimize costs: prices, royalties

• Make IP available: PPO’s, NGO’s, Governments

Sustainability:

• Offset R&D costs: funding, tax credits

• Provide markets: AMC’s, developed world

• Policy support: reimbursement, IP, etc

6

Potential Biotech Contributions

Products Capabilities

Some Companies

All Companies

7

One Company’s Approach Seek out leaders in the field

Focus on ways we can add value

Provide IP in “field” to non-profit partner

Retain IP rights, if any, outside “field”

Start small and work with funders to grow

8

Genzyme/DNDi Partnership: African Tryps

Identify novel inhibitors of polyamine biosynthesis

Genzyme Compounds impacting polyamine metabolism and other pathways Synthetic medicinal chemistry and pharmaceutical development

DNDI Expertise in disease biology In vitro and in vivo testing Resources, network and infrastructure to execute clinical trials

One lead has shown superior results; optimization on going

9

Genzyme/Broad/MMV Partnership: Malaria

Goal: Sustainable pipeline of novel clinical candidates

Exploit existing drug candidates and screens

Utilize new genomic database to identify novel targets

Develop chemical genetics screens to validate targets

Support partners in conducting clinical trials

10

Conclusions

Perceived barriers act as real barriers

Perceptions can reflect an obsolete environment

Solutions to the real problems are not easy

The future belongs to those who see opportunities